Citations

Clear

2511 citation(s) found for "Yang, Yu".

Towards Automated Quality Assurance: Integrating Deep Learning and Classical ML into the Digital Radiography Pipeline
Chen, Hsuan‐Yu , Chou, Cheng‐Fu , Liao, Sheng-Hung, Wu, Mia , Chen, Kuan-Yi, Yang, Ta-Wei , Chang, Chih‐Hao , Fan, Jungwei Wilfred, Chang, Chih-Hao , Fan, Jungwei

Mayo Clinic

Diagnostics | July 6, 2026 | Volume: 16 | Issue: 13 | Pages: 2111

10.3390/diagnostics16132111 | PMID 42449892 Get It

Background/Objectives: To develop and evaluate a deep learning-based quality control system for Lumbar Spinal Digital Radiographs (LSDR), designed to automate and improve their evaluation and reduce reliance on manual reviews. Methods: This retrospective study utilized a deep learning workflow comprising image segmentation, feature extraction, and a classification model. The dataset, including anteroposterior (AP) and lateral (LAT) X-ray images, was expanded through data augmentation techniques. Four U-Net-based models were assessed: standard U-Net, Swin-UNet, Attention U-Net, and Attention U-Net with the weight map, with the latter selected for its superior performance. Extracted features, such as brightness, contrast, and anatomical positioning, were used in an XGBoost classifier, which was evaluated using mean intersection over union (mIoU), accuracy, sensitivity, specificity, and AUC. Results: The Attention U-Net with weighted attention outperformed the other models, achieving high mIoU scores in both AP and LAT views. The XGBoost classifier achieved the best performance in classifying images as “qualified” or “unqualified,” with an AUC of approximately 0.9, high accuracy, and balanced sensitivity and specificity. This approach effectively addressed class imbalances and improved model accuracy compared to traditional machine learning models such as MLP and SVM. Conclusions: The developed automated quality control system demonstrated potential for enhancing image quality, enhancing diagnostic reliability, and optimizing clinical workflow efficiency.
Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer
Arai, Hiroyuki , Elliott, Andrew , Yang, Yan , Farrell, Alex, Millstein, Joshua , Ou, Fang‐Shu , Innocenti, Federico, Wang, Jingyuan , Jayachandran, Priya , Algaze, Sandra, Soni, Shivani, 张武, Scott, Aaron J. , Hwang, Jimmy J., Weinberg, Benjamin A., Marshall, John, Xiu, Joanne, Korn, W. Michael, Venook, Alan P., Lenz, Heinz‐Josef , Lenz, Heinz-Josef , Arai, Hiroyuki , Elliott, Andrew , Yang, Yan , Millstein, Joshua , Ou, Fang-Shu , Wang, Jingyuan , Jayachandran, Priya , Goldberg, Richard M , Lou, Emil , Goel, Sanjay , Innocenti, Federico , Battaglin, Francesca , Algaze, Sandra , Goldberg, Richard M. , Hall, Michael J. , Lou, Emil , Weinberg, Benjamin A. , Marshall, John L , Goel, Sanjay , Joanne, Xiu, Korn, Wolfgang Michael , Venook, Alan P.

Mayo Clinic

No container title available | July 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10164107/v1 | PMID 42427862 Get It

Abstract Endocytosis regulates receptor trafficking and signaling, yet its role in colorectal cancer (CRC) remains unclear. We analyzed transcriptomic data from 15,025 CRC tumors to evaluate gene expression in clathrin-mediated endocytosis (CME) and the endosomal sorting complexes required for transport (ESCRT) pathway. Pathway-level signatures were compared across consensus molecular subtypes (CMS) and examined in relation to oncogenic signaling programs, while individual endocytosis-related genes were evaluated for associations with clinical outcomes in an independent randomized trial cohort. Expression of CME and ESCRT pathways varied by CMS, with the highest expression in CMS4 and the lowest in CMS3. Endocytosis signatures correlated with multiple oncogenic signaling pathways, including MAPK, TGF-β, WNT, PI3K, NOTCH, and angiogenesis, suggesting broad links between endocytic activity and tumor biology. In the randomized phase III CALGB/SWOG 80405 trial, low expression of AP2M1 —a core adaptor in the CME complex—was significantly associated with longer overall survival and progression-free survival in patients treated with anti-EGFR agents, but not in those receiving anti-VEGF agents. These findings suggest that endocytic trafficking may be associated with oncogenic signaling and differential therapeutic benefit in patients with metastatic CRC. The endocytosis pathway reflects biologically relevant heterogeneity in CRC and may help guide therapeutic stratification.
A Novel Dosing Strategy for Tacrolimus in Lung Transplant Recipients: Integrating Machine Learning with Population Pharmacokinetic Analysis
Cai, Xiao-jun, Chen, Yan, Yang, Hang, Huang, Y N , Lu, Ying-rong, Zhou, Wen-Bo, Shi, Lingzhi , Chen, Jing-yu, Wu, B, Huang, Yuan, Li, Ziran , Li, Feng , Lu, Pei‐Hua

Mayo Clinic

Therapeutic Drug Monitoring | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ftd.0000000000001495 | PMID 42397045 Get It

Background: Integrating machine learning (ML) with population pharmacokinetic (PPK) modeling may improve therapeutic drug monitoring predictions. Methods: Tacrolimus trough concentrations from lung transplant patients were split into a training data set (1151 concentrations in 80 patients) and a testing data set (224 concentrations in 20 patients). A PPK model was developed using NONMEM, followed by the development of 10 ML models to fit individual pharmacokinetic parameters from the PPK model with Bayesian forecasting. The best performing ML model was selected as the final model. Both the final PPK and ML models were compared for prediction performance. A web-based dashboard was established with R-shiny to recommend dosing regimens based on patient data. Results: In the PPK model, postoperative days, hematocrit, aspartate aminotransferase, tacrolimus daily dose, coadministered voriconazole or posaconazole, and the CYP3A5*3 genotype were identified significant covariates on the clearance. The Cubist ML model outperformed the PPK model, showing lower root mean squared error for tacrolimus concentrations in the testing data set. An online web-based precision dosing dashboard was created, accessible at (https://tac-dose-ml.shinyapps.io/shiny/). Conclusions: Integrating ML with PPK modeling could yield superior tacrolimus concentration predictions for lung transplant patients, offering an efficient alternative to Bayesian forecasting. The online dashboard provides rapid, individualized dosing recommendations.
Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy
Naseem, Zehra, Prado, Renan, Aggarwal, Manik, Nasser, Jason, Wu, Yueqi, Yang, Qijun, McMichael, John, Kundu, Rupayan, Funk, Cynthia, Ford, Andrew, Simons-Linares, C. Roberto, Naseem, Zehra , Kaul, Ridhima , Chatterjee, Arjun , Aggarwal, Manik , Yang, Qijun , Kundu, Rupayan , Ford, Andrew M. , Simons-Linares, C. Roberto , Rubio‐Tapia, Alberto

Mayo Clinic

Scandinavian Journal of Gastroenterology | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/00365521.2026.2696878 | PMID 42390964 Get It

Renovascular disease induces functionally relevant, locus-specific alterations to DNA methylation and hydroxymethylation in swine scattered tubular-like cells
Iyer, Vinaya C., Shivam, Kumar, Kazeminia, Sara , Zhu, Xiang-Yang, Tang, Hui, Xue, Ailing, Chade, Alejandro , Lerman, Lilach O. , Herrmann, Sandra, Irazabal, Maria V , Lerman, Lilach O , Eirin, Alfonso , Kazeminia, Sara , Herrmann, Sandra M. , Irazabal, María V. , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Renal Physiology | July 2, 2026 | Volume: 331 | Issue: 2 | Pages: F213-F224

10.1152/ajprenal.00055.2026 | PMID 42390182 Get It

Scattered tubular-like cells (STCs) are dedifferentiated renal tubular cells that repair other damaged kidney cells. This study shows that renovascular disease (RVD) induces site-specific 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) modifications in DNA associated with transcriptional changes and impaired proliferative capacity of swine STCs, which could be mitigated in RVD-STCs treated with an epigenetic modulator. Therefore, our observations may contribute to the development of novel approaches to preserve the reparative capacity of STCs in individuals with RVD.
Toward autonomous robotic-assisted and microrobotic surgery
Yang, Sungyun , Kang, Byung Ha , Min, Hyeongho , Wachs, Juan , Alambeigi, Farshid , Desai, Jaydev P. , Yaeger, Kurt , Anderson, Katherine, Kuntz, Alan , Alterovitz, Ron , Webster, Robert J. , Hata, Nobuhiko , Reisenauer, Janani , Clinch, McKenna, Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Kim, Peter C., Huang, Alex S. , Zhang, Hao F. , Riviere, Cameron N. , Henderson, Eric R. , Yip, Michael C. , Dong, Xiaoguang , Wollin, Daniel , Mair, Lamar O. , Karpelson, Michael , Wood, Robert J. , Cohen, Itai , Strano, Michael S. , Wachs, Juan P , Dupont, Pierre E , Yaeger, Kurt , Anderson, Katherine , Kuntz, Alan , Alterovitz, Ron , Webster, Robert J , Hata, Nobuhiko , Reisenauer, Janani S , Clinch, McKenna , Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Sun, Cheng , Zhang, Hao F , Riviere, Cameron N , Henderson, Eric R , Yip, Michael , Dong, Xiaoguang , Wollin, Daniel A , Gracias, David H , Mair, Lamar O , Karpelson, Michael , Wood, Robert J , Cohen, Itai , Strano, Michael S

Mayo Clinic

Science Advances | July 1, 2026 | Volume: 12 | Issue: 27 | Pages: No page available

10.1126/sciadv.aec4197 | PMID 42384805 Get It

Autonomous robotic-assisted surgery (RAS) has emerged as a promising objective in biomedical technology, further enhanced by miniaturization toward microrobotic-assisted surgery (μ-RAS). This reduction in scale promises minimally invasive, partially or fully automated surgical procedures, with the potential to reduce patient recovery times, lower medical costs, and enable previously unavailable procedural options. This perspective highlights the specific advances in RAS that potentially map to the microscale (μ-RAS), organized across five surgical domains: endovascular, endoluminal, laparoscopic, ophthalmic, and orthopedic. We examine both clinical demands and technological advances in surgical robotics and identify the key innovations required for progress across these surgical fields. Our contribution is distinct in combining the perspectives of both surgical experts and bioengineering innovators, outlining a roadmap for the advancement and eventual integration of autonomous RAS and μ-RAS into mainstream surgical practice.
Surgically Diagnosed Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia in Asymptomatic Patients
Chen, Le , Matsuura, Yosuke , Yang, Ruxue, Fickel, Abigail, Ning, Guangyao, Sun, C J , Fickel, Abigail

Mayo Clinic

Surgical Case Reports | June 30, 2026 | Volume: 12 | Issue: 1 | Pages: n/a

10.70352/scrj.cr.26-0123 | PMID 42404090 Get It

Targeting Cellular Pseudo-Senescence to Overcome PARP inhibitors Resistance in BRCA1 -Mutated Breast Cancer
Chatla, Srinivas , Indulkar, Shreya, Kim, Dongwook, Wei, Xiaoyu, Liao, Yun , Yang, Dan, Pompetti, Anthony , Calendo, Gennaro , Edmonston, Tina, Wang, L, Huang, Jian , Chatla, Srinivas , Tian, Zhen , Wang, Congli , Edmonston, Tina Bocker , Lou, Zhenkun , Skórski, Tomasz

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.25.734617 Get It

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a mainstay therapy for homologous recombination (HR)-deficient cancers; however, resistance remains a major clinical challenge. Previously, through a genome wide CRISPR screen, we identified ZNF251 haploinsufficiency as a novel driver of PARPi resistance. In BRCA1 -mutant ( BRCA1 mut ) cells, ZNF251 deficiency led to HR hyperactivation, conferring PARPi resistance that could be reversed by RAD51 inhibition. In this study, we further show that ZNF251 deficiency induces replication stress and a pseudo-senescence state, in which cells exhibit molecular and phenotypic markers of senescence while retaining proliferative capacity. Because senomorphic and senolytic therapies can target senescent cells, we tested whether these approaches could overcome PARPi resistance in ZNF251 -deficient breast cancer cells. Critically, targeting this senescence-like state with either senomorphic agents, such as cytokine inhibitors, or senolytic agents, such as BCL-2 and BCL-XL inhibitors, overcame PARPi resistance ex vivo and in vivo . Importantly, pseudo-senescence was also observed in other PARPi-resistant contexts driven by HR hyperactivation, including 53BP1 - and Shieldin -mutant cells, suggesting that it may represent a broader mechanism underlying PARPi resistance in breast cancer. Furthermore, in two olaparib-resistant, BRCA -mutant triple-negative breast cancer organoid models, treatment with DT2216, a BCL-XL–targeting PROTAC, sensitized both models to olaparib. Together, our work defines a novel pathway linking HR hyperactivation, replication stress, and pseudo-senescence, and positions both senomorphic and senolytic therapies as promising strategies to overcome PARPi resistance in BRCA1 mut breast cancer. Highlights ZNF251 deficiency drives PARP inhibitor resistance through HR hyperactivation, replication stress, and pseudo-senescence in BRCA1 -mutant breast cancer. Senomorphic and senolytic therapies overcome PARP inhibitor resistance in vitro , in vivo , and in patient-derived organoid models. Pseudo-senescence represents a shared vulnerability of HR-hyperactivated PARPi-resistant cancers and can be therapeutically targeted.
Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma
Li, Binbin , Yang, Jingchun , Cai, Meina , Yee, Shelby K., Carlson, Danielle M. , Baker, Darren J. , Ilyas, Sumera I. , Baker, Darren J , Ilyas, Sumera Irie , Carlson, Danielle Marie , Smoot, Rory L. , Li, B.

Mayo Clinic

No container title available | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.24.734341 Get It

ABSTRACT Cholangiocarcinoma (CCA) is a lethal biliary cancer in which chemoresistance is nearly universal, and its tumor immune microenvironment is dominated by immunosuppressive tumor-associated macrophages (TAMs) that exclude cytotoxic CD8 + T cells. How tumor cells sustain this immunosuppressive state during chemotherapy is undefined. Here we demonstrate that therapy-induced senescent-like (Sen-L) cancer cells accumulate after gemcitabine/cisplatin in human and murine CCA, are predominantly cancer cells, and predict shorter survival. Genetic elimination of Sen-L cancer cells reduces tumor burden, lowers TAM abundance, and restores intratumoral CD8 + T cells, establishing them as causal drivers. Growth differentiation factor 15 (GDF-15) is the dominant Sen-L-secreted factor and reprograms macrophages to suppress CD8 + T cells through the non-canonical receptor TGFBR2 and STAT6, and p16-restricted Gdf15 silencing phenocopies Sen-L elimination. Combined with chemotherapy, Sen-L elimination improves survival beyond chemotherapy alone. These findings establish Sen-L cancer cells and their GDF-15 output as causal, targetable drivers of macrophage-mediated immune evasion in CCA. SIGNIFICANCE STATEMENT Therapy-induced senescent-like cancer cells, not stromal cells, are the dominant senescent-like and immunosuppressive population in cholangiocarcinoma, and their elimination restores antitumor immunity. GDF-15 is their dominant secreted effector and engages a non-canonical macrophage receptor, TGFBR2, identifying a cancer-cell-to-macrophage axis and a Sen-L-elimination strategy to restore chemosensitivity. Abstract Figure Graphical abstract. Senescent-like CCA cells promote tumor immunosuppression through TAMs polarization by GDF-15